Zola H
Clin Exp Immunol. 1975 Feb;19(2):367-76.
Administration of antilymphocytic serum (ALS) or alloantiserum at the time of graft both stimulate enhanced growth of a tumour allograft, but the effect of alloantiserum is weaker and more dependent on dose. Both antisera suppress (or delay) the development of lymphocyte-mediated cytotoxicity, and partly inhibit the development of activated, cytostatic macrophages. Apart from these central or afferent effects, ALS added to an in vitro culture of immune effector cells and EL4 target cells strongly inhibits cytotoxicity, while in this model, alloantiserum is less effective in this respect. The relevance of the effects observed in vitro to in vivo facilitation of allografts is discussed.
在移植时给予抗淋巴细胞血清(ALS)或同种异体抗血清均会刺激肿瘤同种异体移植的生长增强,但同种异体抗血清的作用较弱且更依赖于剂量。两种抗血清均抑制(或延迟)淋巴细胞介导的细胞毒性的发展,并部分抑制活化的细胞抑制性巨噬细胞的发展。除了这些中枢或传入效应外,添加到免疫效应细胞和EL4靶细胞的体外培养物中的ALS强烈抑制细胞毒性,而在该模型中,同种异体抗血清在这方面效果较差。讨论了体外观察到的效应与体内同种异体移植促进作用的相关性。